The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Combined loss of PUMA and p21 accelerates c-MYC-driven lymphoma development considerably less than loss of one allele of p53
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The observation that deficiency of Puma (or combined deficiency of Puma and Noxa or Puma and p21) promoted the development of C-myc-driven lymphoma,107,108 which suggested that p53-mediated apoptosis could exert obvious tumor-suppressive effects.”
From p53: from understanding its structure to advances in therapeutic targeting (2026) · cites this paper as [107]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Transcriptional control of human p53-regulated genes
Riley, T., Sontag, E., Chen, P., & Levine, A. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2395 · Cited by 1,921
Zhang, Y., Xiong, Y., & Yarbrough, W. G. (1998) · Cell · doi:10.1016/s0092-8674(00)81401-4 · Cited by 1,626
Pomerantz, J., Schreiber-Agus, N., Liégeois, N. J., Silverman, A., Alland, L., Chin, L., Potes, J., Chen, K., Orlow, I., Lee, H.-W., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81400-2 · Cited by 1,521
p53- and Drug-Induced Apoptotic Responses Mediated by BH3-Only Proteins Puma and Noxa
Villunger, A., Michalak, E. M., Coultas, L., Müllauer, F., Böck, G., Ausserlechner, M. J., Adams, J. M., & Strasser, A. (2003) · Science · doi:10.1126/science.1090072 · Cited by 1,327
Self-citationRadiation-induced cell cycle arrest compromised by p21 deficiency
Brugarolas, J., Chandrasekaran, C., Gordon, J. I., Beach, D., Jacks, T., & Hannon, G. J. (1995) · Nature · doi:10.1038/377552a0 · Cited by 1,242
Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2
Kamijo, T., Weber, J. D., Zambetti, G., Zindy, F., Roussel, M. F., & Sherr, C. J. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.14.8292 · Cited by 899
Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis
Eischen, C. M., Weber, J. D., Roussel, M. F., Sherr, C. J., & Cleveland, J. L. (1999) · Genes & Development · doi:10.1101/gad.13.20.2658 · Cited by 819
Tumor suppression by Ink4a-Arf: progress and puzzles.
Lowe, S. W., & Sherr, C. J. (2003) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(02)00013-8 · Cited by 699
Deconstructing p53 transcriptional networks in tumor suppression
Bieging, K. T., & Attardi, L. D. (2012) · Trends in Cell Biology · doi:10.1016/j.tcb.2011.10.006 · Cited by 194
Research works printed but not linked: 37
- Lane DP . p53, guardian of the genome. Nature 1992; 358: 15–16. · DOI · Paper page
- Levine AJ . p53, the cellular gatekeeper for growth and division. Cell 1997; 88: 323–331. · DOI · Paper page
- Vogelstein B, Lane D, Levine AJ . Surfing the p53 network. Nature 2000; 408: 307–310. · DOI · Paper page
- Vousden KH, Lane DP . p53 in health and disease. Nat Rev Mol Cell Biol 2007; 8: 275–283. · DOI · Paper page
- Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CAJ, Butel JS et al. Mice deficient for p53 are developmentally normal but are susceptible to spontaneous tumours. Nature 1992; 356: 215–221. · DOI · Paper page
- Jacks T, Remington L, Williams BO, Schmitt EM, Halachmi S, Bronson RT et al. Tumor spectrum analysis in p53-mutant mice. Curr Biol 1994; 4: 1–7. · DOI · Paper page
- Michalak EM, Jansen ES, Happo L, Cragg MS, Tai L, Smyth GK et al. Puma and to a lesser extent Noxa are suppressors of Myc-induced lymphomagenesis. Cell Death Differ 2009; 16: 684–696. · DOI · Paper page
- Garrison SP, Jeffers JR, Yang C, Nilsson JA, Hall MA, Rehg JE et al. Selection against PUMA gene expression in Myc-driven B-cell lymphomagenesis. Mol Cell Biol 2008; 28: 5391–5402. · DOI
- Adams JM, Harris AW, Pinkert CA, Corcoran LM, Alexander WS, Cory S et al. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 1985; 318: 533–538. · DOI · Paper page
- Jeffers JR, Parganas E, Lee Y, Yang C, Wang J, Brennan J et al. Puma is an essential mediator of p53-dependent and -independent apoptotic pathways. Cancer Cell 2003; 4: 321–328. · DOI · Paper page
- Hanahan D, Weinberg RA . The hallmarks of cancer. Cell 2000; 100: 57–70. · DOI · Paper page
- Deng C, Zhang P, Harper JW, Elledge SJ, Leder P . Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 1995; 82: 675–684. · DOI · Paper page
- Newbold A, Salmon JM, Martin BP, Stanley K, Johnstone RW . The role of p21(waf1/cip1) and p27(Kip1) in HDACi-mediated tumor cell death and cell cycle arrest in the Emu-myc model of B-cell lymphoma. Oncogene 2014; 33: 5415–5423. · DOI
- Patino-Garcia A, Sotillo-Pineiro E, Sierrasesumaga-Ariznabarreta L . p21WAF1 mutation is not a predominant alteration in pediatric bone tumors. Pediatr Res 1998; 43: 393–395. · DOI
- McKenzie KE, Siva A, Maier S, Runnebaum IB, Seshadri R, Sukumar S . Altered WAF1 genes do not play a role in abnormal cell cycle regulation in breast cancers lacking p53 mutations. Clin Cancer Res 1997; 3: 1669–1673.
- Shiohara M, el-Deiry WS, Wada M, Nakamaki T, Takeuchi S, Yang R et al. Absence of WAF1 mutations in a variety of human malignancies. Blood 1994; 84: 3781–3784. · DOI · Paper page
- Jackson RJ, Adnane J, Coppola D, Cantor A, Sebti SM, Pledger WJ . Loss of the cell cycle inhibitors p21(Cip1) and p27(Kip1) enhances tumorigenesis in knockout mouse models. Oncogene 2002; 21: 8486–8497. · DOI
- Topley GI, Okuyama R, Gonzales JG, Conti C, Dotto GP . p21(WAF1/Cip1) functions as a suppressor of malignant skin tumor formation and a determinant of keratinocyte stem-cell potential. Proc Natl Acad Sci USA 1999; 96: 9089–9094. · DOI · Paper page
- Adnane J, Jackson RJ, Nicosia SV, Cantor AB, Pledger WJ, Sebti SM . Loss of p21WAF1/CIP1 accelerates Ras oncogenesis in a transgenic/knockout mammary cancer model. Oncogene 2000; 19: 5338–5347. · DOI
- Yang WC, Mathew J, Velcich A, Edelmann W, Kucherlapati R, Lipkin M et al. Targeted inactivation of the p21(WAF1/cip1) gene enhances Apc-initiated tumor formation and the tumor-promoting activity of a Western-style high-risk diet by altering cell maturation in the intestinal mucosal. Cancer Res 2001; 61: 565–569.
- Wang YA, Elson A, Leder P . Loss of p21 increases sensitivity to ionizing radiation and delays the onset of lymphoma in atm-deficient mice. Proc Natl Acad Sci USA 1997; 94: 14590–14595. · DOI · Paper page
- Martin-Caballero J, Flores JM, Garcia-Palencia P, Serrano M . Tumor susceptibility of p21(Waf1/Cip1)-deficient mice. Cancer Res 2001; 61: 6234–6238.
- Bearss DJ, Lee RJ, Troyer DA, Pestell RG, Windle JJ . Differential effects of p21(WAF1/CIP1) deficiency on MMTV-ras and MMTV-myc mammary tumor properties. Cancer Res 2002; 62: 2077–2084.
- Martins CP, Berns A . Loss of p27(Kip1) but not p21(Cip1) decreases survival and synergizes with MYC in murine lymphomagenesis. EMBO J 2002; 21: 3739–3748. · DOI
- Barboza JA, Liu G, Ju Z, El-Naggar AK, Lozano G . p21 delays tumor onset by preservation of chromosomal stability. Proc Natl Acad Sci USA 2006; 103: 19842–19847. · DOI
- Post SM, Quintas-Cardama A, Terzian T, Smith C, Eischen CM, Lozano G . p53-dependent senescence delays Emu-myc-induced B-cell lymphomagenesis. Oncogene 2010; 29: 1260–1269. · DOI
- Valente LJ, Gray DH, Michalak EM, Pinon-Hofbauer J, Egle A, Scott CL et al. p53 efficiently suppresses tumor development in the complete absence of its cell-cycle inhibitory and proapoptotic effectors p21, Puma, and Noxa. Cell Rep 2013; 3: 1339–1345. · DOI · Paper page
- Li T, Kon N, Jiang L, Tan M, Ludwig T, Zhao Y et al. Tumor suppression in the absence of p53-mediated cell-cycle arrest, apoptosis, and senescence. Cell 2012; 149: 1269–1283. · DOI · Paper page
- Aubrey BJ, Kelly GL, Kueh AJ, Brennan MS, O'Connor L, Milla L et al. An inducible lentiviral guide rna platform enables the identification of tumor-essential genes and tumor-promoting mutations in vivo. Cell Rep 2015; 10: 1422–1432. · DOI · Paper page
- Harris AW, Pinkert CA, Crawford M, Langdon WY, Brinster RL, Adams JM . The Eμ-myc transgenic mouse: a model for high-incidence spontaneous lymphoma and leukemia of early B cells. J Exp Med 1988; 167: 353–371. · DOI · Paper page
- Langdon WY, Harris AW, Cory S, Adams JM . The c-myc oncogene perturbs B lymphocyte development in Eμ-myc transgenic mice. Cell 1986; 47: 11–18. · DOI · Paper page
- Strasser A, Elefanty AG, Harris AW, Cory S . Progenitor tumours from Em-bcl-2-myc transgenic mice have lymphomyeloid differentiation potential and reveal developmental differences in cell survival. EMBO J 1996; 15: 3823–3834. · DOI
- Strasser A, Harris AW, Bath ML, Cory S . Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2. Nature 1990; 348: 331–333. · DOI · Paper page
- Nakano K, Vousden KH . PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell 2001; 7: 683–694. · DOI · Paper page
- Jiang D, Brady CA, Johnson TM, Lee EY, Park EJ, Scott MP et al. Full p53 transcriptional activation potential is dispensable for tumor suppression in diverse lineages. Proc Natl Acad Sci USA 2011; 108: 17123–17128. · DOI
- Hoffman B, Liebermann DA . Apoptotic signaling by c-MYC. Oncogene 2008; 27: 6462–6472. · DOI · Paper page
- Brady CA, Jiang D, Mello SS, Johnson TM, Jarvis LA, Kozak MM et al. Distinct p53 transcriptional programs dictate acute DNA-damage responses and tumor suppression. Cell 2011; 145: 571–583. · DOI · Paper page
Cited by
How does p53 induce apoptosis and how does this relate to p53-mediated tumour suppression
Aubrey, B. J., Kelly, G. L., Janic, A., Herold, M. J., & Strasser, A. (2018) · Cell Death & Differentiation · doi:10.1038/cdd.2017.169 · Cited by 1,395
Self-citationALOX12 is required for p53-mediated tumour suppression through a distinct ferroptosis pathway
Chu, B., Kon, N., Chen, D., Li, T., Liu, T., Jiang, L., Song, S., Tavana, O., & Gu, W. (2019) · Nature Cell Biology · doi:10.1038/s41556-019-0305-6 · Cited by 882
Cell cycle arrest through indirect transcriptional repression by p53: I have a DREAM
Engeland, K. (2018) · Cell Death & Differentiation · doi:10.1038/cdd.2017.172 · Cited by 656
Apoptotic cell death in disease—Current understanding of the NCCD 2023
Vitale, I., Pietrocola, F., Guilbaud, E., Aaronson, S. A., Abrams, J. M., Adam, D., Agostini, M., Agostinis, P., Alnemri, E. S., Altucci, L., et al. (2023) · Cell Death & Differentiation · doi:10.1038/s41418-023-01153-w · Cited by 361
Self-citationShamloo, B., & Usluer, S. (2019) · Cancers · doi:10.3390/cancers11081178 · Cited by 336
Metadata
- Authors
- Valente, L. J., Grabow, S., Vandenberg, C. J., Strasser, A., & Janic, A.
- Venue
- Oncogene
- Published
- 2015-12-07
- Volume
- 35
- Issue
- 29
- Pages
- 3866-3871
- ISSN
- 0950-9232
- 1476-5594
- Cited by
- 37
- References
- 9
- Language
- en
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Combined loss of PUMA and p21 accelerates c-MYC-driven lymphoma development considerably less than loss of one allele of p53. https://app.cochat.ai/papers/10.1038/onc.2015.457
- The paper
- Valente, L. J., Grabow, S., Vandenberg, C. J., Strasser, A., & Janic, A. (2016). Combined loss of PUMA and p21 accelerates c-MYC-driven lymphoma development considerably less than loss of one allele of p53. Oncogene. https://doi.org/10.1038/onc.2015.457
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.